Insulin signalling: new target for Parkinson's treatments?

The Lancet

Volumn 390, Issue 10103, 2017, Pages 1628-1630

  Poewe, Werner ^a   Seppi, Klaus ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; SOMATOMEDIN C; NEUROPROTECTIVE AGENT;

APOPTOSIS; AUTOPHAGY; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG TARGETING; FOREBRAIN; HUMAN; INFLAMMATION; INSULIN SIGNALING; NEUROIMAGING; NOTE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNIFIED PARKINSON DISEASE RATING SCALE; INSULIN RESISTANCE;

HUMANS; INSULIN; INSULIN RESISTANCE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 85028084920     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32101-3     Document Type: Note

References (11)

1. Poewe, WSK, Tanner, CM, Halliday, GM, et al. Parkinson disease. Nat Rev Dis Primers, 23, 2017, 17013.
2. de la Monte, SM, Insulin resistance and neurodegeneration: progress towards the development of new therapeutics for Alzheimer's disease. Drugs 77 (2017), 47–65.
3. Calsolaro, V, Edison, P, Novel GLP-1 (glucagon-like peptide-1) analogues and insulin in the treatment for Alzheimer's disease and other neurodegenerative diseases. CNS Drugs 29 (2015), 1023–1039.
4. Hughes, R, Nikolic, K, Ramsay, RR, One for all? Hitting multiple Alzheimer disease targets with one drug. Frontier Neurosci, 25, 2016, 177.
5. Athauda, D, Foltynie, T, Insulin resistance and Parkinson's disease: a new target for disease modification?. Prog Neurobiol 145–46 (2016), 98–120.
6. Kim, DS, Choi, HI, Wang, Y, Luo, Y, Hoffer, BJ, Greig, NH, A new treatment strategy for Parkinson's disease through the gut–brain axis: the glucagon-like peptide-1 receptor pathway. Cell Transplant, 2017 published online April 26. DOI: 10.3727/096368917X695669.
7. Aviles-Olmos, I, Dickson, J, Kefalopoulou, Z, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinsons Dis 4 (2014), 337–344.
8. Athauda, D, Maclagan, K, Skene, SS, et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet, 2017 published online Aug 3. http://dx.doi.org/10.1016/S0140-6736(17)31585-4.
9. Li, Y, Perry, T, Kindy, MS, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and parkinsonism. Proc Natl Acad Sci USA 106 (2009), 1285–1290.
10. MacConell, L, Gurney, K, Malloy, J, Zhou, M, Kolterman, O, Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4328 patients. Diabetes Metab Syndr Obes 8 (2015), 241–253.
11. Reddy, IA, Pino, JA, Weikop, P, et al. Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels. Transl Psychiatry, 6, 2016, e809.